Literature DB >> 7748965

Risk of human immunodeficiency virus (HIV) transmission by anti-HIV-negative blood components in Germany and Austria.

D W Schwartz1, G Simson, K Baumgarten, H Fabritz, J Riggert, H Neumeyer, W R Mayr, M Köhler.   

Abstract

In order to estimate the residual risk of transfusion-transmitted HIV infection we have analyzed the data from two transfusion centers in Austria (Vienna) and Germany (Göttingen) from 1985 to 1994. In Vienna, an incidence of 1:42,000 positive anti-HIV tests in repeat donors and a prevalence of 1:7000 in first-time donors were found in 1993. In Göttingen, the indicence was 1:67,000 and the prevalence 1:7900 from 1985 to 1993. Based on a mathematical model which takes (a) the window period and (b) the false-negative rate of anti-HIV tests, as well as (c) human and operational errors into consideration, we have calculated the residual risk of HIV infection. The residual risk (third generation anti-HIV test) was found to be 1:520,000 (95% confidence interval 1:1340,000-1:210,000), and 1:900,000 (95% confidence interval 1:2340,000-1:380,000) for Vienna and Göttingen, respectively, in 1993. Look-back studies from 1985 till 1994 revealed transfusion-transmitted HIV infections in three recipients (for 1.9 million donations in Vienna) and one recipient (for 160,000 donations in Göttingen) of blood components. Based on our model, as well as on prevalence and incidence rates of HIV infection, it is also possible to predict the efficacy of additional measures introduced to further decrease the risk of transfusion-transmitted HIV infection through blood components.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7748965     DOI: 10.1007/BF01700377

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  16 in total

1.  Duration of human immunodeficiency virus infection before detection of antibody.

Authors:  C R Horsburgh; C Y Ou; J Jason; S D Holmberg; I M Longini; C Schable; K H Mayer; A R Lifson; G Schochetman; J W Ward
Journal:  Lancet       Date:  1989-09-16       Impact factor: 79.321

2.  [Prevalence of HIV antibodies in blood donors in the West Germany and West Berlin].

Authors:  D Glück; K Koerner; G Caspari; G Elbert; W Grässmann; R Hesse; G Holzberger; B Kostuch; J Sternberger; A Vornwald
Journal:  Dtsch Med Wochenschr       Date:  1987-10-16       Impact factor: 0.628

Review 3.  HIV and blood transfusions: focus on seroconversion.

Authors:  M P Busch
Journal:  Vox Sang       Date:  1994       Impact factor: 2.144

4.  Early detection of antibodies to HIV-1 by third-generation assays.

Authors:  H L Zaaijer; P v Exel-Oehlers; T Kraaijeveld; E Altena; P N Lelie
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

5.  Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HIV-1 and HTLV-I/II infections.

Authors:  K E Nelson; J G Donahue; A Muñoz; N D Cohen; P M Ness; A Teague; V A Stambolis; D H Yawn; B Callicott; H McAllister
Journal:  Ann Intern Med       Date:  1992-10-01       Impact factor: 25.391

6.  Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group.

Authors:  L R Petersen; G A Satten; R Dodd; M Busch; S Kleinman; A Grindon; B Lenes
Journal:  Transfusion       Date:  1994-04       Impact factor: 3.157

7.  Risk of developing AIDS after primary acute HIV-1 infection.

Authors:  A Sinicco; R Fora; M Sciandra; A Lucchini; P Caramello; P Gioannini
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-06

8.  Thirteen current anti-HIV-1/HIV-2 enzyme immunoassays: how accurate are they?

Authors:  L McAlpine; J Gandhi; J V Parry; P P Mortimer
Journal:  J Med Virol       Date:  1994-02       Impact factor: 2.327

9.  Transmission of HIV by transfusion of HIV-screened blood: the value of a national register. The 'Recipients' Study Group of the French Society of Blood Transfusion.

Authors:  F Courtois; A M Jullien; F Chenais; L Noel; F Pinon
Journal:  Transfus Med       Date:  1992-03       Impact factor: 2.019

10.  HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients.

Authors:  I Loussert-Ajaka; T D Ly; M L Chaix; D Ingrand; S Saragosti; A M Couroucé; F Brun-Vézinet; F Simon
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

View more
  2 in total

1.  Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.

Authors:  Jo Anne Chiavetta; Michael Escobar; Alice Newman; Yaohua He; Pete Driezen; Shelley Deeks; Devon E Hone; Sheila F O'Brien; Graham Sher
Journal:  CMAJ       Date:  2003-10-14       Impact factor: 8.262

2.  Risk of hepatitis C virus (HCV) transmission by anti-HCV-negative blood components in Austria and Germany.

Authors:  J Riggert; D W Schwartz; A Uy; G Simson; F Jelinek; H Fabritz; W R Mayr; M Köhler
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.